TARS today
$75.94-$0.95 (-1.24%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourLeaning Bearish
15 minBearish
5 minConsolidating
Daily trend turns up above $76.27
Key levels
Resistance$83.94
Resistance$76.27
Support$70.03
Support$65.34
Latest news & SEC filings
SEC FilingTarsus Pharmaceuticals, Inc. filed an insider trading report (Form 4)
AnalystMizuho lifts its Tarsus Pharmaceuticals valuation to $102
AnalystGuggenheim keeps Buy rating on Tarsus Pharmaceuticals, lifts target to $97
All TARS news →About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals develops and sells medicines, with an initial focus on treatments for the eye. Its approved product, XDEMVY, is an eye drop for Demodex blepharitis, an eyelid condition caused by mites. The company is also working on product candidates for ocular rosacea and for preventing Lyme disease. It sells mainly to eye doctors and their patients in the United States.
Based on the company's 10-K filed Feb 23, 2026.
Nasdaq · Healthcare
Tarsus Pharmaceuticals, Inc. (TARS)
What Is the Price Target for TARS?
SEPT Low Target
$89.00
SEPT Mid Target
$100.00
SEPT High Target
$116.00
Analyst Consensus
$100.00
Is TARS a Buy or Sell Right Now?
Thesis
- •Revenue growing 146.7% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TARS.
Start Free Trial →Is TARS Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$80.08
22
Moat Score
NONE
4/9
Piotroski Score
8.7
Altman Z-Score
What Is Smart Money Doing with TARS?
Insider Signal
SELLING
0 buys / 17 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| YARNO WENDY L | director | Buy | 302 | - | Sep 15, 2026 |
| LINK WILLIAM J PHD | director | Buy | 201 | - | Sep 15, 2026 |
| LINK WILLIAM J PHD | director | Sale | 11,675 | $915K | Sep 15, 2026 |
| LINK WILLIAM J PHD | director | Sale | 759 | $60K | Sep 15, 2026 |
| LINK WILLIAM J PHD | director | Sale | 66 | $5K | Sep 15, 2026 |
| PYOTT DAVID E I | director | Buy | 201 | - | Sep 15, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →TARS Growth Story
Revenue YoY
146.7%
3yr Revenue CAGR
159.5%
EPS Growth YoY
48.21%
FCF Growth YoY
73.6%
Revenue Trend
ACCELERATING
Dark Pool Trades for TARS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for TARS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:43:02 | $76.50 | 1,000 | $$77K | SELL |
| 14:42:45 | $76.50 | 3,300 | $$252K | MIDPOINT |
| 14:42:45 | $76.50 | 1,100 | $$84K | MIDPOINT |
| 14:42:44 | $76.50 | 1,000 | $$77K | MIDPOINT |
| 14:42:44 | $76.50 | 1,000 | $$77K | MIDPOINT |
5 dark pool trades shown · $$566K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Tarsus Pharmaceuticals, Inc. (TARS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TARS — frequently asked questions
What is TARS stock price today?
Tarsus Pharmaceuticals, Inc. (TARS) is at $75.94, down 1.24% (-$0.95) at the Nov 13, 2026 close.
Why is TARS stock moving today?
Latest TARS news — Nov 5, 2026: Tarsus Pharmaceuticals, Inc. filed an insider trading report (Form 4) · Nov 5, 2026: Mizuho lifts its Tarsus Pharmaceuticals valuation to $102
What is the TARS price target?
The average analyst price target for TARS is $100.00, ranging from $89 to $116, based on 5 analysts.
What do analysts rate TARS?
Analyst ratings for TARS: 0 Buy, 6 Hold, 0 Sell — consensus Hold.
Did TARS beat earnings?
TARS last reported on Aug 6, 2026: EPS -$0.43 vs -$0.19 expected — a miss of 124.2%.
Does TARS pay a dividend?
TARS does not currently pay a dividend.
How much debt does TARS have?
Tarsus Pharmaceuticals, Inc. reported $73M of debt and $205M of cash (Jun 30, 2026).
What are TARS support and resistance levels?
Support: $70.03, $65.34, $61.51. Resistance: $76.27, $83.94, $91.53.
What are insiders doing with TARS?
Insider activity: SELLING, 0 buys and 17 sells in the last 90 days.
What is the latest news on TARS?
Nov 5, 2026: Tarsus Pharmaceuticals, Inc. filed an insider trading report (Form 4) · Nov 5, 2026: Mizuho lifts its Tarsus Pharmaceuticals valuation to $102 · Nov 5, 2026: Guggenheim keeps Buy rating on Tarsus Pharmaceuticals, lifts target to $97